ReachMD CME

By ReachMD

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncolo... more

· Medicine

4.3

33 ratings

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about ReachMD CME:

How many episodes does ReachMD CME have?

The podcast currently has 2,875 episodes available.

ReachMD CME episodes:

April 30, 2024 ACC 2024: VOYAGER PAD Part 2
CME credits: 0.75
Valid until: 20-06-2025
Claim your CME credit at https://reachmd.com/programs/cme/acc-2024-voyager-pad-part-2/24407/

This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions and the 92nd European Atherosclerosis Society (EAS) Congress. From clinical trials like PIONEER-AF, VOYAGER PAD, SHASTA 2 and MUIR to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
...more
6min
April 30, 2024 ACC 2024: VOYAGER PAD Part 1
CME credits: 0.75
Valid until: 20-06-2025
Claim your CME credit at https://reachmd.com/programs/cme/acc-2024-voyager-pad-part-1/24406/

This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions and the 92nd European Atherosclerosis Society (EAS) Congress. From clinical trials like PIONEER-AF, VOYAGER PAD, SHASTA 2 and MUIR to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
...more
6min
April 30, 2024 ACC 2024: What's Really New in Electrophysiology That Will Change My Practice?
CME credits: 0.75
Valid until: 20-06-2025
Claim your CME credit at https://reachmd.com/programs/cme/acc-2024-whats-really-new-in-electrophysiology-that-will-change-my-practice/24405/

This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions and the 92nd European Atherosclerosis Society (EAS) Congress. From clinical trials like PIONEER-AF, VOYAGER PAD, SHASTA 2 and MUIR to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
...more
6min
April 30, 2024 ACC 2024: The PIONEER AF-PCI Trial
CME credits: 0.75
Valid until: 20-06-2025
Claim your CME credit at https://reachmd.com/programs/cme/acc-2024-the-pioneer-af-pci-trial/24404/

This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions and the 92nd European Atherosclerosis Society (EAS) Congress. From clinical trials like PIONEER-AF, VOYAGER PAD, SHASTA 2 and MUIR to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
...more
5min
April 30, 2024 Not All Therapy Needs to Be Swallowed or Injected: The Future of Digital Therapeutics to Alleviate the Negative Symptoms of Schizophrenia
CME credits: 1.00
Valid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/not-all-therapy-needs-to-be-swallowed-or-injected-the-future-of-digital-therapeutics-to-alleviate-the-negative-symptoms-of-schizophrenia/20300/

This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
...more
5min
April 30, 2024 Integration Is the Key to Success: How Will the New SCZ Therapies Fit Into Clinical Treatment Paradigms?
CME credits: 1.00
Valid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/integration-is-the-key-to-success-how-will-the-new-scz-therapies-fit-into-clinical-treatment-paradigms/20299/

This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
...more
5min
April 30, 2024 Unraveling the Overlapping Negative and Cognitive Symptoms in Schizophrenia
CME credits: 1.00
Valid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/unraveling-the-overlapping-negative-and-cognitive-symptoms-in-schizophrenia/20294/

This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
...more
6min
April 30, 2024 Understanding CIAS: What Does Current Literature Say About the Etiology and Pathophysiology of CIAS?
CME credits: 1.00
Valid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/understanding-cias-what-does-current-literature-say-about-the-etiology-and-pathophysiology-of-cias/20291/

This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
...more
5min
April 30, 2024 Challenges of Integrating Cognitive Remediation in CIAS
CME credits: 1.00
Valid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/challenges-of-integrating-cognitive-remediation-in-cias/20296/

This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
...more
5min
April 30, 2024 Making the Case for Dual Ang-2/VEGF-A Inhibition: Anatomical Benefits
CME credits: 0.25
Valid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/making-the-case-for-dual-ang-2vegf-a-inhibition-anatomical-benefits/18009/

What evidence do we have that blocking Ang-2 and VEGF-A is beneficial for patients? Tune in to hear Dr. Jennifer Lim and Dr. Carl Regillo examine the anatomical and biomarker evidence surrounding dual inhibition of Ang-2 and VEGF-A. Find out how bispecific targeting can benefit patients with neovascular age-related macular degeneration and diabetic macular edema.
=
...more
16min

FAQs about ReachMD CME:

How many episodes does ReachMD CME have?

The podcast currently has 2,875 episodes available.